Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03888612 · ClinicalTrials.gov registry record · Phase 1
Trial of ARV-110 in Patients With Metastatic Castration Resistant Prostate Cancer
A Phase 1 study, sponsored by Arvinas.
- Completed
- Registry status
- Phase 1
- Development phase
- 248
- Enrollment target
NCT03888612 is a Phase 1 study that has completed, run by Arvinas. The registered enrollment target is 248 participants.
The verdict
NCT03888612, a Phase 1 study, has completed, sponsored by Arvinas.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 248 participants
- Enrollment target
Study Summary
Phase 1/2 dose escalation study to assess the safety and tolerability of ARV-110 in men with mCRPC who have progressed on prior approved systemic therapies for their castrate resistant disease (one of which must be enzalutamide or abiraterone).
Interventions
- DRUG ARV-110
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 248 participants |
| Start Date | 2019-03-01 |
| Est. Completion | 2025-01-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03888612
The ClinicalTrials.gov registry entry for NCT03888612 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 248 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Arvinas, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ARV-110 is the first listed.
NCT03888612 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03888612 about?
NCT03888612 is a clinical study titled "Trial of ARV-110 in Patients With Metastatic Castration Resistant Prostate Cancer". Phase 1/2 dose escalation study to assess the safety and tolerability of ARV-110 in men with mCRPC who have progressed on prior approved systemic therapies for their castrate resistant disease (one of which must be enzalutamide or abiraterone).
What is the current status of trial NCT03888612?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 248 participants. The study started on 2019-03-01. Estimated completion is 2025-01-27.
What interventions are being tested in trial NCT03888612?
The interventions under investigation include: ARV-110 (DRUG).
Who is sponsoring clinical trial NCT03888612?
This trial is sponsored by Arvinas, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.